• Optimind Pharma (OMND) will begin trading on the CSE under the ticker symbol OMND
  • Optimind is a shareholder of Manitari Pharma
  • Manitari Pharma has submitted an application to Health Canada for a Controlled Substances Dealer’s Licence
  • Optimind specializes in prescribing medical cannabis and psychedelic-assisted therapies for various medical ailments

Optimind Pharma (OMND) will begin trading on the CSE under the ticker symbol OMND.

Medical cannabis has quickly become one of the most prescribed medications in Canada due to its efficacy and safety, which remains the primary business of the clinic.

Optimind is also an emerging provider of psychedelic therapies at its clinic, helping people suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities by providing ketamine assisted treatment and other psychedelic enhanced psychotherapy modalities.

Optimind is a shareholder of Manitari Pharma. Manitari Pharma has submitted an application to Health Canada for a Controlled Substances Dealer’s Licence for Psilocybin Research Purposes.

Tomas Sipos, Chief Executive Officer at Optimind, commented on the news.

“The public listing of Optimind represents a significant milestone in the growth of our company. It’s an important step that will help facilitate our mission to provide psychedelic-assisted therapies for the public and improve their quality of life.”

Tony Clement, Chair of the Advisory Board at Optimind added,

“Optimind is on it’s way to becoming a leader in psychedelic-assisted therapy that will provide patients throughout North America with choices that promote mental, physical, and spiritual wellness. I’m supportive and enthusiastic to be a part of this exciting development and opportunity.”

“Psychedelic-assisted therapy has the power to drastically transform people’s lives around the world. At Optimind, our mission is to help people live life fully again through our treatment,” commented Dr. Michael Hart, Chief Operating Officer at Optimind.

Optimind specializes in prescribing medical cannabis and other alternative treatments for various medical ailments.


More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.